[go: up one dir, main page]

DE60229961D1 - Antikörper enthaltende stabilisierte zubereitungen - Google Patents

Antikörper enthaltende stabilisierte zubereitungen

Info

Publication number
DE60229961D1
DE60229961D1 DE60229961T DE60229961T DE60229961D1 DE 60229961 D1 DE60229961 D1 DE 60229961D1 DE 60229961 T DE60229961 T DE 60229961T DE 60229961 T DE60229961 T DE 60229961T DE 60229961 D1 DE60229961 D1 DE 60229961D1
Authority
DE
Germany
Prior art keywords
antibodies containing
containing stabilized
stabilized preparations
acetyltryptophan
preparations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229961T
Other languages
English (en)
Inventor
Tadao Yamazaki
Hiroko Konishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE60229961D1 publication Critical patent/DE60229961D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DE60229961T 2001-08-29 2002-08-29 Antikörper enthaltende stabilisierte zubereitungen Expired - Lifetime DE60229961D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001258988 2001-08-29
PCT/JP2002/008732 WO2003018056A1 (fr) 2001-08-29 2002-08-29 Preparations stabilisees contenant un anticorps

Publications (1)

Publication Number Publication Date
DE60229961D1 true DE60229961D1 (de) 2009-01-02

Family

ID=19086420

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229961T Expired - Lifetime DE60229961D1 (de) 2001-08-29 2002-08-29 Antikörper enthaltende stabilisierte zubereitungen

Country Status (6)

Country Link
US (1) US7682608B2 (de)
EP (1) EP1428537B1 (de)
JP (1) JP4342941B2 (de)
AT (1) ATE414537T1 (de)
DE (1) DE60229961D1 (de)
WO (1) WO2003018056A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
JP4253688B2 (ja) * 2006-11-30 2009-04-15 三洋化成工業株式会社 凍結乾燥用保護剤及び生理活性物質の製造方法
AR064826A1 (es) * 2007-01-09 2009-04-29 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
CA2687291A1 (en) * 2007-05-16 2008-11-20 Ktb Tumorforschungsgesellschaft Mbh Low-viscous anthracycline formulation
JP4812807B2 (ja) * 2007-06-27 2011-11-09 三洋化成工業株式会社 タンパク質含有水溶液安定化剤及びタンパク質含有水溶液の安定化方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20110086163A1 (en) * 2009-10-13 2011-04-14 Walbar Inc. Method for producing a crack-free abradable coating with enhanced adhesion
EP2637690B1 (de) 2010-11-11 2016-09-21 AbbVie Biotechnology Ltd Anti-tnf-alpha-antikörper-flüssigformulierungen mit hoher konzentration
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
EP2968466B1 (de) * 2013-03-13 2018-07-25 F.Hoffmann-La Roche Ag Formulierungen mit reduzierter oxydation
CN104977408B (zh) * 2015-06-15 2016-09-14 暨南大学 一种筛选分泌特异性单克隆抗体杂交瘤细胞的方法与应用
CA3007491A1 (en) * 2015-12-30 2017-07-06 Genentech, Inc. Use of tryptophan derivatives for protein formulations
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3875852T2 (de) 1987-08-10 1993-03-18 Miles Inc Gereinigtes igm.
US5157113A (en) 1987-08-10 1992-10-20 Miles Inc. Removal of nucleic acids from monoclonal antibody preparations
CA2049342A1 (en) 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
JPH0768137B2 (ja) 1989-06-15 1995-07-26 株式会社ミドリ十字 アルブミン製剤及びその製法
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AUPO871997A0 (en) 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
IL138801A0 (en) 1998-04-03 2001-10-31 Chugai Pharmaceutical Co Ltd Humanized antibody against human tissue factor and process for the preparation thereof
JP4683810B2 (ja) * 2000-02-29 2011-05-18 中外製薬株式会社 長期安定化製剤

Also Published As

Publication number Publication date
US7682608B2 (en) 2010-03-23
WO2003018056A1 (fr) 2003-03-06
EP1428537A4 (de) 2005-11-09
EP1428537A1 (de) 2004-06-16
US20040213785A1 (en) 2004-10-28
ATE414537T1 (de) 2008-12-15
JP4342941B2 (ja) 2009-10-14
JPWO2003018056A1 (ja) 2004-12-09
EP1428537B1 (de) 2008-11-19

Similar Documents

Publication Publication Date Title
DE60229961D1 (de) Antikörper enthaltende stabilisierte zubereitungen
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
EP1674480A4 (de) Antikörper, der den die tgf-beta-aktivierung steuernden regionsabschnitt erkennt
NO2017028I1 (no) eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
DE60329489D1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
DE69638269D1 (de) Hochaffine humane antikörper gegen tumorantigene
DK1454138T3 (da) Immunocytokiner med moduleret selektivitet
EP1698640A4 (de) Verfahren zur stabilisierung von antikörpern und stabilisierte antikörperzubereitung vom lösungstyp
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
DE69333800D1 (de) Thioether enthaltende Konjugate
BR9408167A (pt) Composto composição fungicida e método de controle de doenças em plantas
EE200300408A (et) Aktiivsete valkude saagise suurendamine
DK1025227T3 (da) Humane TOLL-homologer
DE50209000D1 (de) PH-Wert-geregeltes Polyamidpulver
EP1542721A4 (de) Modifizierte "s" antikörper
DE60332711D1 (de) Neue insektizide proteine von bazillus thuringiensis
ITBO20010545A0 (it) Articolo per la coltivazione di specie orticole
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DK0501215T3 (da) Fusionsproteiner indeholdende monoklonalt antistof, linker og beta-glucuronidase til pro-drug-aktivering, deres fremstillin
DE60012713D1 (de) Durch xanthurensäure modifizierte proteine
DE60124230D1 (de) Pseudovirus-partikel des rotavirus und ihre verwendung als vektoren für proteine und nukleinsäuren
WO2003057821A3 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
EP1191037A4 (de) Mittel zur stabilisierung von hämoglobinen
ATE249478T1 (de) Harnstoff- und thioharnstoffderivate von antibiotisch wirksamen glykopeptiden
ATE402959T1 (de) Antifucoidan antikörper

Legal Events

Date Code Title Description
8364 No opposition during term of opposition